Maple syrup urine disease

Mechanisms and management

Patrick R. Blackburn, Jennifer M. Gass, Filippo Pinto e Vairo, Kristen M. Farnham, Herjot K. Atwal, Sarah Macklin, Eric W Klee, Paldeep S. Atwal

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Maple syrup urine disease (MSUD) is an inborn error of metabolism caused by defects in the branched-chain α-ketoacid dehydrogenase complex, which results in elevations of the branched-chain amino acids (BCAAs) in plasma, α-ketoacids in urine, and production of the pathognomonic disease marker, alloisoleucine. The disorder varies in severity and the clinical spectrum is quite broad with five recognized clinical variants that have no known association with genotype. The classic presentation occurs in the neonatal period with developmental delay, failure to thrive, feeding difficulties, and maple syrup odor in the cerumen and urine, and can lead to irreversible neurological complications, including stereotypical movements, metabolic decompensation, and death if left untreated. Treatment consists of dietary restriction of BCAAs and close metabolic monitoring. Clinical outcomes are generally good in patients where treatment is initiated early. Newborn screening for MSUD is now commonplace in the United States and is included on the Recommended Uniform Screening Panel (RUSP). We review this disorder including its presentation, screening and clinical diagnosis, treatment, and other relevant aspects pertaining to the care of patients.

Original languageEnglish (US)
Pages (from-to)57-66
Number of pages10
JournalApplication of Clinical Genetics
Volume10
DOIs
StatePublished - Sep 6 2017

Fingerprint

Maple Syrup Urine Disease
Disease Management
Branched Chain Amino Acids
Cerumen
3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)
Urine
Acer
Inborn Errors Metabolism
Failure to Thrive
Isoleucine
Patient Care
Therapeutics
Genotype
Newborn Infant

Keywords

  • Alloisoleucine
  • BCKDHA
  • BCKDHB
  • Branched-chain amino acids
  • DBT
  • Maple syrup urine disease
  • Newborn screening

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Blackburn, P. R., Gass, J. M., Pinto e Vairo, F., Farnham, K. M., Atwal, H. K., Macklin, S., ... Atwal, P. S. (2017). Maple syrup urine disease: Mechanisms and management. Application of Clinical Genetics, 10, 57-66. https://doi.org/10.2147/TACG.S125962

Maple syrup urine disease : Mechanisms and management. / Blackburn, Patrick R.; Gass, Jennifer M.; Pinto e Vairo, Filippo; Farnham, Kristen M.; Atwal, Herjot K.; Macklin, Sarah; Klee, Eric W; Atwal, Paldeep S.

In: Application of Clinical Genetics, Vol. 10, 06.09.2017, p. 57-66.

Research output: Contribution to journalReview article

Blackburn, PR, Gass, JM, Pinto e Vairo, F, Farnham, KM, Atwal, HK, Macklin, S, Klee, EW & Atwal, PS 2017, 'Maple syrup urine disease: Mechanisms and management', Application of Clinical Genetics, vol. 10, pp. 57-66. https://doi.org/10.2147/TACG.S125962
Blackburn, Patrick R. ; Gass, Jennifer M. ; Pinto e Vairo, Filippo ; Farnham, Kristen M. ; Atwal, Herjot K. ; Macklin, Sarah ; Klee, Eric W ; Atwal, Paldeep S. / Maple syrup urine disease : Mechanisms and management. In: Application of Clinical Genetics. 2017 ; Vol. 10. pp. 57-66.
@article{978aa6eeab5249af97e861cd10bacb3e,
title = "Maple syrup urine disease: Mechanisms and management",
abstract = "Maple syrup urine disease (MSUD) is an inborn error of metabolism caused by defects in the branched-chain α-ketoacid dehydrogenase complex, which results in elevations of the branched-chain amino acids (BCAAs) in plasma, α-ketoacids in urine, and production of the pathognomonic disease marker, alloisoleucine. The disorder varies in severity and the clinical spectrum is quite broad with five recognized clinical variants that have no known association with genotype. The classic presentation occurs in the neonatal period with developmental delay, failure to thrive, feeding difficulties, and maple syrup odor in the cerumen and urine, and can lead to irreversible neurological complications, including stereotypical movements, metabolic decompensation, and death if left untreated. Treatment consists of dietary restriction of BCAAs and close metabolic monitoring. Clinical outcomes are generally good in patients where treatment is initiated early. Newborn screening for MSUD is now commonplace in the United States and is included on the Recommended Uniform Screening Panel (RUSP). We review this disorder including its presentation, screening and clinical diagnosis, treatment, and other relevant aspects pertaining to the care of patients.",
keywords = "Alloisoleucine, BCKDHA, BCKDHB, Branched-chain amino acids, DBT, Maple syrup urine disease, Newborn screening",
author = "Blackburn, {Patrick R.} and Gass, {Jennifer M.} and {Pinto e Vairo}, Filippo and Farnham, {Kristen M.} and Atwal, {Herjot K.} and Sarah Macklin and Klee, {Eric W} and Atwal, {Paldeep S.}",
year = "2017",
month = "9",
day = "6",
doi = "10.2147/TACG.S125962",
language = "English (US)",
volume = "10",
pages = "57--66",
journal = "Application of Clinical Genetics",
issn = "1178-704X",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Maple syrup urine disease

T2 - Mechanisms and management

AU - Blackburn, Patrick R.

AU - Gass, Jennifer M.

AU - Pinto e Vairo, Filippo

AU - Farnham, Kristen M.

AU - Atwal, Herjot K.

AU - Macklin, Sarah

AU - Klee, Eric W

AU - Atwal, Paldeep S.

PY - 2017/9/6

Y1 - 2017/9/6

N2 - Maple syrup urine disease (MSUD) is an inborn error of metabolism caused by defects in the branched-chain α-ketoacid dehydrogenase complex, which results in elevations of the branched-chain amino acids (BCAAs) in plasma, α-ketoacids in urine, and production of the pathognomonic disease marker, alloisoleucine. The disorder varies in severity and the clinical spectrum is quite broad with five recognized clinical variants that have no known association with genotype. The classic presentation occurs in the neonatal period with developmental delay, failure to thrive, feeding difficulties, and maple syrup odor in the cerumen and urine, and can lead to irreversible neurological complications, including stereotypical movements, metabolic decompensation, and death if left untreated. Treatment consists of dietary restriction of BCAAs and close metabolic monitoring. Clinical outcomes are generally good in patients where treatment is initiated early. Newborn screening for MSUD is now commonplace in the United States and is included on the Recommended Uniform Screening Panel (RUSP). We review this disorder including its presentation, screening and clinical diagnosis, treatment, and other relevant aspects pertaining to the care of patients.

AB - Maple syrup urine disease (MSUD) is an inborn error of metabolism caused by defects in the branched-chain α-ketoacid dehydrogenase complex, which results in elevations of the branched-chain amino acids (BCAAs) in plasma, α-ketoacids in urine, and production of the pathognomonic disease marker, alloisoleucine. The disorder varies in severity and the clinical spectrum is quite broad with five recognized clinical variants that have no known association with genotype. The classic presentation occurs in the neonatal period with developmental delay, failure to thrive, feeding difficulties, and maple syrup odor in the cerumen and urine, and can lead to irreversible neurological complications, including stereotypical movements, metabolic decompensation, and death if left untreated. Treatment consists of dietary restriction of BCAAs and close metabolic monitoring. Clinical outcomes are generally good in patients where treatment is initiated early. Newborn screening for MSUD is now commonplace in the United States and is included on the Recommended Uniform Screening Panel (RUSP). We review this disorder including its presentation, screening and clinical diagnosis, treatment, and other relevant aspects pertaining to the care of patients.

KW - Alloisoleucine

KW - BCKDHA

KW - BCKDHB

KW - Branched-chain amino acids

KW - DBT

KW - Maple syrup urine disease

KW - Newborn screening

UR - http://www.scopus.com/inward/record.url?scp=85029582759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029582759&partnerID=8YFLogxK

U2 - 10.2147/TACG.S125962

DO - 10.2147/TACG.S125962

M3 - Review article

VL - 10

SP - 57

EP - 66

JO - Application of Clinical Genetics

JF - Application of Clinical Genetics

SN - 1178-704X

ER -